These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 17285592)
21. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. Mosca A; Berruti A; Russo L; Torta M; Dogliotti L J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864 [TBL] [Abstract][Full Text] [Related]
22. Augmented expression of chromogranin A and serotonin in peri-malignant benign prostate epithelium as compared to adenocarcinoma. Sion-Vardy N; Tzikinovsky A; Bolotyn A; Segal S; Fishman D Pathol Res Pract; 2004; 200(7-8):493-9. PubMed ID: 15462496 [TBL] [Abstract][Full Text] [Related]
23. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643 [TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine differentiation in the progression of prostate cancer. Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524 [TBL] [Abstract][Full Text] [Related]
25. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353 [TBL] [Abstract][Full Text] [Related]
26. Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells. Untergasser G; Plas E; Pfister G; Heinrich E; Berger P Prostate; 2005 Sep; 64(4):419-29. PubMed ID: 15800938 [TBL] [Abstract][Full Text] [Related]
27. [Multidrug resistance and its relationship with neuroendocrine differentiation in non-small cell lung carcinoma]. Yu SP; Xiong YY; Tian SF Zhonghua Jie He He Hu Xi Za Zhi; 2003 Mar; 26(3):165-8. PubMed ID: 12816683 [TBL] [Abstract][Full Text] [Related]
28. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases]. Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184 [TBL] [Abstract][Full Text] [Related]
32. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients]. Leibovitch I; Pinthus Y; Sella BA; Ramon J Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720 [TBL] [Abstract][Full Text] [Related]
33. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991 [TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. Hayashi T; Matsubara A; Ohara S; Mita K; Hasegawa Y; Usui T; Arihiro K; Norimura S; Sentani K; Oue N; Yasui W Oncol Rep; 2009 Jan; 21(1):95-100. PubMed ID: 19082448 [TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study. Hirano D; Jike T; Okada Y; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Yoshida T; Takimoto Y Ultrastruct Pathol; 2005; 29(5):367-75. PubMed ID: 16257863 [TBL] [Abstract][Full Text] [Related]
36. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study. Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133 [TBL] [Abstract][Full Text] [Related]
37. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896 [TBL] [Abstract][Full Text] [Related]
38. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Sheridan T; Herawi M; Epstein JI; Illei PB Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190 [TBL] [Abstract][Full Text] [Related]
39. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. Berruti A; Mosca A; Porpiglia F; Bollito E; Tucci M; Vana F; Cracco C; Torta M; Russo L; Cappia S; Saini A; Angeli A; Papotti M; Scarpa RM; Dogliotti L J Urol; 2007 Sep; 178(3 Pt 1):838-43; quiz 1129. PubMed ID: 17631319 [TBL] [Abstract][Full Text] [Related]
40. Chromogranin A, neuron-specific enolase and synaptophysin as neuroendocrine cell markers in the diagnosis of tumours of the gastro-entero-pancreatic system. Schürmann G; Betzler M; Buhr HJ Eur J Surg Oncol; 1990 Aug; 16(4):298-303. PubMed ID: 2116326 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]